Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) Sees Large Decline in Short Interest

Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) saw a significant decline in short interest in October. As of October 15th, there was short interest totalling 33,700 shares, a decline of 18.0% from the September 30th total of 41,100 shares. Based on an average trading volume of 521,500 shares, the short-interest ratio is presently 0.1 days. Approximately 1.7% of the company’s stock are short sold.

Shuttle Pharmaceuticals Stock Up 0.6 %

Shares of NASDAQ:SHPH traded up $0.01 on Wednesday, reaching $1.81. The company had a trading volume of 1,417,425 shares, compared to its average volume of 482,813. The stock has a market cap of $5.34 million, a PE ratio of -0.52 and a beta of -0.94. The company has a 50-day moving average of $1.53. Shuttle Pharmaceuticals has a twelve month low of $1.03 and a twelve month high of $4.95.

Shuttle Pharmaceuticals (NASDAQ:SHPH) last released its earnings results on Tuesday, September 3rd. The company reported ($0.96) earnings per share (EPS) for the quarter.

Shuttle Pharmaceuticals Company Profile

Shuttle Pharmaceuticals Holdings, Inc, a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers .